In the past, we've spoken with two people who understand what it takes to move a novel therapy from molecule to market: Kabir Nath, CEO of Compass Pathways, and Michael Gold, the company's Chief R&D Officer. Their conversations revealed something clin ops teams know oh so well… great science means little without flawless execution.
On November 4th, that execution paid off. Compass announced it expects a potential FDA approval decision in late 2026 or early 2027, nine to twelve months earlier than planned. The September FDA meeting yielded two wins: positive discussions regarding a potential rolling NDA submission, and COMP006 trial enrollment completing ahead of schedule.
"With the completion of COMP006 enrollment and our recent positive discussions with the FDA, we are excited about pulling forward our expected launch timing," Nath stated in the Q3 earnings release. "There clearly is significant momentum behind psychedelics."
The acceleration stems from operational discipline, not clinical shortcuts. Compass now projects Q1 2026 readout of combined 9-week COMP006 data alongside 26-week COMP005 data, with full 26-week COMP006 results in early Q3 2026. The rolling submission allows FDA review to begin before final trial completion.
Quality First, Timeline Second
"The best designed clinical trial, the best study… if it's not executed correctly, it's useless," Gold told us during our conversation. His perspective comes from three decades spanning GSK, J&J, and multiple CNS-focused biotechs. "Quality, time, cost… in that rank order. You have mistakes with quality that you can't really undo with either time or money."
That philosophy shows in the trial architecture. Compass is conducting the largest randomized, controlled, double-blind psilocybin program ever: COMP005 enrolled 258 patients across 32 US sites, while COMP006 targets 568 patients across 96 sites in North America and Europe. COMP005 runs fully blinded for 26 weeks — typically long for depression trials — with both studies including open-label extensions to week 52 for durability and redosing data.
The COMP006 design tests two 25mg doses three weeks apart against lower-dose comparators, directly addressing functional unblinding concerns that contributed to Lykos's August 2024 MDMA rejection. Nath explained the thinking behind the three-dose Phase 2B design (25mg, 10mg, 1mg): "Dr. Guy Goodwin came out with that design in anticipating precisely some of these challenges...for that person coming in for the first time, genuinely distinguish between 10 and 25 is pretty well impossible."
The company caps psychedelic-experienced participants at 15% of enrollment and employs what it terms "psychological support" rather than formalized psychotherapy — critical distinctions given FDA's position that it regulates drugs, not therapy protocols.
Pressure Testing Everything
Gold's approach to trial design centers on relentless pressure testing. "You share it with colleagues or consultants or sometimes even not friends — people who are going to challenge you," he said. "I can ask them: tell me how this is going to fail. They'll without any shame or hesitation tell me just how bad my design is. Which is fine. It's what I need to know."
That methodology extends to operational monitoring. Gold's ideal dashboard tracks patient inflow and retention in real-time, monitors missing data patterns, flags excess variance by site, and surfaces protocol deviations as they emerge. The goal: catching problems when they're manageable.
"At the end of the day, the study may not work or the drug fails," he said. "But everybody can walk away with a clean conscience knowing that you've answered that question."
What It Means
Compass met its June 2025 COMP005 primary endpoint, showing statistically significant MADRS improvement versus placebo at six weeks (p < .001, treatment difference of -3.6 points). No new safety signals emerged, and the Data Safety Monitoring Board reported no clinically meaningful imbalance in suicidality between arms.
The accelerated timeline positions COMP360 as the likely first psilocybin therapy to reach market. With approximately 2.8 million Americans meeting TRD criteria after failing two or more antidepressants, and esketamine (Spravato) seeing strong uptake since its 2019 launch despite requiring frequent clinic visits, the commercial opportunity is substantial.
COMP360's treatment model requires 6-8 hours of monitoring per session versus approximately 2 hours for Spravato, but Compass expects patients will need substantially fewer total administrations. The operational trade-off: longer individual sessions for potentially greater durability.
But the operational dimension matters. As psychedelic trials advance through Phase 3, sponsors face complex operational challenges around functional unblinding protocols and safety monitoring requirements. Compass's timeline acceleration reflects, at minimum, efficient trial execution alongside their clinical data. In a competitive landscape where multiple sponsors are pursuing similar indications, operational execution may influence which candidates reach regulatory review first.
Brandon Li · Co-Founder, Power
For clinical operations teams navigating complex Phase 3 execution: Talk to our team about what we're learning from sponsors at the frontier.
